| Budget Amount *help |
¥127,140,000 (Direct Cost: ¥97,800,000、Indirect Cost: ¥29,340,000)
Fiscal Year 2021: ¥24,960,000 (Direct Cost: ¥19,200,000、Indirect Cost: ¥5,760,000)
Fiscal Year 2020: ¥24,960,000 (Direct Cost: ¥19,200,000、Indirect Cost: ¥5,760,000)
Fiscal Year 2019: ¥24,960,000 (Direct Cost: ¥19,200,000、Indirect Cost: ¥5,760,000)
Fiscal Year 2018: ¥24,960,000 (Direct Cost: ¥19,200,000、Indirect Cost: ¥5,760,000)
Fiscal Year 2017: ¥27,300,000 (Direct Cost: ¥21,000,000、Indirect Cost: ¥6,300,000)
|
|---|
| Outline of Final Research Achievements |
In this research, our research group has provided the next-generation sequence analysis platform, also including a series of template preparation platforms, and primary data analysis platforms to all research groups in this research area. At the same time, this research group has also independently developed and practiced the basic technology for elucidating the diversity of metabolic adaptation during drug response of cancer cells. With a particular focus on gene expression regulations, we attempted to increase the efficiency of transcriptome and epigenome analysis and systematically produce data on omics drug perturbation responses. An information analysis model was constructed across each omics hierarchy starting from the acquired data to understand the elastic response of the cancer cells in drug responses.
|
